Phreesia (NYSE:PHR) Rating Lowered to Hold at Wells Fargo & Company

Phreesia (NYSE:PHR) was downgraded by research analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the company. Robert W. Baird reaffirmed a “neutral” rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Canaccord Genuity Group reduced their price target on Phreesia from $33.00 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. KeyCorp reduced their price target on Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. Citizens Jmp reaffirmed a “market perform” rating on shares of Phreesia in a research report on Wednesday, April 1st. Finally, Citigroup reaffirmed a “neutral” rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $19.06.

Phreesia Price Performance

NYSE PHR opened at $8.84 on Wednesday. The business has a 50 day simple moving average of $9.76 and a 200 day simple moving average of $14.17. Phreesia has a 52-week low of $7.77 and a 52-week high of $32.76. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. The stock has a market cap of $545.74 million, a price-to-earnings ratio of 294.50 and a beta of 0.89.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The business had revenue of $127.07 million for the quarter, compared to the consensus estimate of $126.75 million. During the same period in the previous year, the company posted ($0.11) earnings per share. Phreesia’s revenue for the quarter was up 15.9% compared to the same quarter last year. Analysts anticipate that Phreesia will post 0.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Allison C. Hoffman sold 6,176 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $9.06, for a total value of $55,954.56. Following the completion of the sale, the general counsel owned 157,309 shares of the company’s stock, valued at approximately $1,425,219.54. This represents a 3.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Yvonne Hui sold 10,063 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $9.08, for a total value of $91,372.04. Following the completion of the sale, the insider directly owned 25,991 shares of the company’s stock, valued at approximately $235,998.28. The trade was a 27.91% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 50,493 shares of company stock worth $461,983. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

Several large investors have recently made changes to their positions in PHR. Royal Bank of Canada boosted its holdings in shares of Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after buying an additional 16,309 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock valued at $4,090,000 after buying an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock valued at $1,599,000 after buying an additional 2,158 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after buying an additional 11,181 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Phreesia by 0.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after buying an additional 2,402 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, Portnoy, Levi & Korsinsky, Pomerantz, Schall, Faruqi & Faruqi, and The Gross Law Firm, announced or reiterated class-action claims against Phreesia over alleged investor harm during the May 8, 2025 to March 30, 2026 period, which can weigh on sentiment and raise legal overhang. Article Title
• Negative Sentiment: The lawsuits focus on allegations that Phreesia overstated growth durability and made misleading statements about the AccessOne acquisition, reinforcing concerns about execution and disclosure credibility. Article Title
• Neutral Sentiment: Several notices mainly remind investors about the July 13, 2026 lead-plaintiff deadline, which keeps the legal situation in focus but does not add new operational news for the company. Article Title
• Neutral Sentiment: An article also noted that Phreesia is projected to post quarterly earnings, but it did not provide new fundamental results or guidance, so it is unlikely to be the main driver of the stock’s move. Article Title

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.